Latest Drugs, Latest Approval in CD52 monoclonal antibodies

What are CD52 monoclonal antibodies?

Monoclonal antibodies used in immunotherapy are produced artificially from a cell clone therefore consist of a single type of immunoglobulin. They are targeted towards specific antigens and bind to the antigens to form a complex. The complex can be recognized and destroyed by phagocytes or used for other diagnostic purposes.

Natural antibodies are proteins made by the B-lymphocytes in response to antigens. Each B-cell makes only one type of antibody. For therapeutic purposes a significant amount of a particular antibody is needed. These are obtained from a culture that gives a one type of antibody, which are called monoclonal antibodies.

CD52 antigens are present on lymphocytes. CD52 monoclonal antibodies bind to CD52 antigens and bring about complement and antibody-dependent cell-mediated cytotoxicity. CD52 monoclonal antibodies are used to treat patients with B-cell chronic lymphocytic leukemia (B-CLL).

Name Updated
Alemtuzumab (Alemtuzumab [ al-em-tooz-ue-mab ]) 13-Aug-2023
Lemtrada (Alemtuzumab [ al-em-tooz-ue-mab ]) 05-Aug-2023
Campath (Alemtuzumab [ al-em-tooz-ue-mab ]) 13-Jul-2023